EpiMass joins BioInnovation Institute Venture Lab
EpiMass has received Venture Lab funding from BioInnovation Institute to advance real-time molecular guidance for skin cancer surgery.
Read on LinkedInSingle procedure theranostics
EpiMass aims to enable seamless diagnosis and treatment of skin cancer in a single procedure, reducing fragmentation in clinical workflows and improving patient outcomes.
Our collaborators
Experience surgical guidance with EpiMass!
Hover to classify tissue. Click, hold, and drag to ablate the tumor only.
Live spectral readout
Scanning
ClassificationBackground
Illustration for demonstration purposes only. Not representative of validated clinical data
News
Latest from EpiMass
01Unmet need
Skin cancer care remains fragmented
For most patients, suspicion, biopsy, histopathology, and treatment still happen in separate procedures. That delay adds uncertainty for patients and extra demand on clinics.
Today
Suspicion
Biopsy
Histopathology
Treatment
Typical time to treatmentWeeks to months
With EpiMass
Suspicion
Diagnosis and treatment in one procedure
Typical time to treatmentFirst visit
Disconnected workflow
Diagnosis and treatment often occur in separate steps, across different settings and timelines.
Prolonged uncertainty
Patients may wait between biopsy, histopathology, and treatment planning — a period of significant anxiety.
System-level burden
Repeated visits and fragmented pathways place additional demand on clinicians and healthcare systems.
02The EpiMass approach
An integrated platform for diagnosis and treatment in a single procedure
A surgical laser for tissue ablation, a mass spectrometer for plume analysis, and a classification model for real-time surgical feedback.
- 01
Laser ablation
A surgical laser removes tissue.
- 02
Surgical smoke
Ablation releases a molecular plume.
- 03
Mass spectrometry
Molecular fingerprints are read from the plume in real time.
- 04
Machine learning
A trained model interprets the spectral signal.
- 05
Tissue classification
The tissue class is reported to the surgeon continuously.
Workflow integration
Unifies diagnostic evaluation and treatment in a single clinical visit.
Clinician-centered design
Built with clinicians for usability in everyday dermatology workflows.
Evidence-driven development
Pre-clinical and clinical studies to support adoption and regulatory review.
Development stage
Building toward clinical validation
Concept and prototype work is complete. Pre-clinical evaluation and clinical implementation studies are being initiated, ahead of regulatory engagement.
- Completed
Concept & feasibility
Initial concept development and technical feasibility assessment.
- Completed
Prototype development
Iterative engineering of device prototypes and core technology validation.
- Current stage
Pre-clinical evaluation
Laboratory and pre-clinical studies to establish foundational performance data.
- Current stage
Clinical studies
Clinical implementation studies are being initiated to evaluate safety and performance in practice.
- Planned
Regulatory pathway
Engagement with regulatory frameworks aligned with intended market entry.
Market relevance
A significant and growing clinical need
Keratinocyte carcinoma is the most common cancer. Patients seen in Danish dermatology practice rose 150% over the past ten years.
Patients in Danish dermatology practice
Keratinocyte carcinoma and related NMSC, Hudkræftdatabasen
| Year | Patients per reporting year |
|---|---|
| 14/15 | 12,976 |
| 18/19 | 19,348 |
| 22/23 | 24,967 |
| 23/24 | 29,954 |
| 24/25 | 32,496 |
Hudkræftdatabasen annual report 2024/2025, SundK. Worldwide figure from GBD 2021 (BCC plus SCC).
- Patients in Danish dermatology practice, 2024/25
- 32,496
- Increase over ten years in Danish dermatology practice
- +150%
- New BCC and SCC cases worldwide, 2021 (GBD)
- 6.3M
Patients in Danish dermatology practice, 2024/25
Increase over ten years in Danish dermatology practice
New BCC and SCC cases worldwide, 2021 (GBD)
A single procedure for a costly bottleneck
Separate diagnostic and treatment visits consume clinic time and delay a decision. Diagnosing during treatment would address that central bottleneck in skin cancer care.
03Team
Experienced leadership building toward clinical impact
EpiMass brings together clinicians, analytical scientists, and mass spectrometry pioneers from leading institutions in Denmark, the UK, and Germany.
CEO & Founder
Dr. Lauritz Brorsen
Founder of EpiMass, with research at Bispebjerg Hospital and the University of Copenhagen. He built laser-assisted REIMS to classify keratinocyte carcinoma from a surgical laser plume, and leads the company in transforming that work into clinical utility.
LinkedIn
Distinguished Scientific Advisor
Prof. Zoltan Takats
Pioneer of ambient mass spectrometry and inventor of REIMS and the iKnife. EpiMass applies that foundational method to skin, with approved surgical lasers.
LinkedIn
Clinical Operations Lead
Assoc. Prof. Catharina Lerche
Associate professor at Bispebjerg Hospital and the University of Copenhagen, spanning clinical dermatology and pharmaceutical sciences. She leads the studies that take mass spectrometry for keratinocyte carcinoma from pre-clinical work into the clinic.
LinkedIn
Scientific Advisor
Dr. Daniel Simon
A key contributor to the early development of the iKnife at Imperial College London, with an affiliation at University Hospital Regensburg. He advises EpiMass on technology development and regulatory strategy.
Clinical Advisor
Prof. Merete Hædersdal
Director and Head of Research at the Danish Research Center for Skin Cancer. She advises EpiMass on clinical requirements for intraoperative laser guidance in dermatology.
LinkedIn
Clinical Advisor
Prof. Peter Bjerring
Clinical professor and consultant dermatologist at Aalborg University Hospital and Privathospitalet Mølholm. He advises EpiMass on clinical adoption of intraoperative optical and laser guidance.
LinkedIn
Clinical Implementation Lead
Dr. Jonatan Granborg
Pharmacist and mass spectrometrist at Bispebjerg Hospital and the Danish Research Center for Skin Cancer. He oversees EpiMass clinical studies and advises on implementation in dermatology practice.
LinkedIn
Scientific Advisor
Assoc. Prof. Christian Janfelt
Associate professor of mass spectrometry imaging at the University of Copenhagen. His MALDI and DESI maps of keratinocyte carcinoma define the signals EpiMass later reads from the plume.
LinkedIn04FAQ
Frequently asked questions
Epi refers to the epidermis, the outer layer of the skin. Mass refers to mass spectrometry, the method used to read molecular signals from tissue during the procedure.
Concept and prototype stages are complete. Pre-clinical evaluation and clinical implementation studies are being initiated.
Not yet. No clinical outcomes are reported publicly. Results will be shared as studies generate data.
Frameworks will match the intended classification and markets. Milestones will be communicated as the pathway advances.
We welcome engagement from clinical investigators, healthcare institutions, strategic partners, and investors who share our commitment to advancing skin cancer care through evidence-based innovation.
No. EpiMass is not commercially available and is not approved for clinical use. The technology is in development and subject to clinical evaluation and regulatory review.
Please reach out via the email address in our contact section or footer. We respond to inquiries from investors, clinical partners, and collaborators.
05Contact
Let's advance skin cancer care together
Whether you are an investor, clinical partner, or collaborator, we welcome the opportunity to discuss how EpiMass can contribute to better patient outcomes.
Get in touch at
contact@epimass.com